Seaweed-derived Rhamnan Sulfate and Vascular Function

The University of Texas System (UT)

Status: Enrolling

Conditions: Cardiovascular Diseases

Treatments: Dietary Supplement: Rhamnan sulfate

Study type: Interventional

Funder types: Other

Identifiers

NCT05651230

STUDY00003693

Details and patient eligibility

About

The primary aim of the proposed investigation is to examine the hypothesis that a relatively short period of rhamnan sulfate supplementation would improve key markers of vascular dysfunction in middle-aged and older adults with at least one risk factors for cardiovascular disease.

Enrollment: 15 estimated patients

Sex: All

Ages: 35 to 85 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• at least one risk factor for cardiovascular disease (e.g., dyslipidemia, hypertension, obesity, impaired fasting glucose)
• a BMI of <40 kg/m2

Exclusion criteria

• gastrointestinal disorders and/or renal disease
• pregnancy or lactation
• strenuous physical activity (>3 times/week)
• alcohol abuse

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

15 participants in 2 patient groups, including a placebo group

Rhamnan sulfate

Experimental group

Description:

The subjects will take rhamnan sulfate (Rhamnox100, Konan Chemical Manufacturing Co. LTD, Mie, Japan: 540 mg/day) orally three time daily at each meal time.

Treatment:

Dietary Supplement: Rhamnan sulfate

Placebo

Placebo Comparator group

Description:

The subjects will take placebo (Konan Chemical Manufacturing Co. LTD, Mie, Japan: 540 mg/day) orally three time daily at each meal time.

Treatment:

Dietary Supplement: Rhamnan sulfate